Chen Ma

Ms. Chen Ma

Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2005 in Plant Foods for Human Nutrition
Verified
Journal Article
Closed access
PDF file
YPYong Peng
Yong Peng
CMChen Ma
Chen Ma
YLYawei Li
Yawei Li
Kelvin LeungKelvin Leung
Kelvin Leung
ZJZhi-Hong Jiang
Zhi-Hong Jiang
ZZZhong-Zhen Zhao
Zhong-Zhen Zhao

30 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
HGHui-Hui Guo
Hui-Hui Guo
CFChen-Lin Feng
Chen-Lin Feng
WZWenxuan Zhang
Wenxuan Zhang
ZLZhi-Gang Luo
Zhi-Gang Luo
HZHong-Juan Zhang
Hong-Juan Zhang
JJJian-dong Jiang
Jian-dong Jiang
Cardiovascular and metabolic disease (CMD) remains a main cause of premature death worldwide. Berberine (BBR), a lipid-lowering botanic compound with diversified potency against metabolic disorders, is a promising candidate for ameliorating CMD. The liver is the target of BBR so that liver-site accumulation could be important for fulfilling its therapeutic effect. In this study a rational designed micelle (CTA-Mic) consisting of α-tocopheryl hydrophobic core and on-site detachable polyethylene glycol-thiol shell is developed for effective liver deposition of BBR. The bio-distribution analysis proves that the accumulation of BBR in liver is increased by 248.8% assisted by micelles. Up-regulation of a range of energy-related genes is detectable in the HepG2 cells and in vivo. In the high fat diet-fed mice, BBR-CTA-Mic intervention remarkably improves metabolic profiles and reduces the formation of aortic arch plaque. Our results provide proof-of-concept for a liver-targeting strategy to ameliorate CMD using natural medicines facilitated by Nano-technology.

1 August 2013 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
YFYong Fang
Yong Fang
ZCZipeng Cao
Zipeng Cao
QHQi Hou
Qi Hou
CMChen Ma
Chen Ma
CYChunsuo Yao
Chunsuo Yao
CHChuanshu Huang
Chuanshu Huang
Isorhapontigenin (ISO) is a new derivative of stilbene compound that was isolated from the Chinese herb Gnetum Cleistostachyum and has been used for treatment of bladder cancers for centuries. In our current studies, we have explored the potential inhibitory effect and molecular mechanisms underlying isorhapontigenin anticancer effects on anchorage-independent growth of human bladder cancer cell lines. We found that isorhapontigenin showed a significant inhibitory effect on human bladder cancer cell growth and was accompanied with related cell cycle G0–G1 arrest as well as downregulation of cyclin D1 expression at the transcriptional level in UMUC3 and RT112 cells. Further studies identified that isorhapontigenin downregulated cyclin D1 gene transcription via inhibition of specific protein 1 (SP1) transactivation. Moreover, ectopic expression of GFP-cyclin D1 rendered UMUC3 cells resistant to induction of cell-cycle G0–G1 arrest and inhibition of cancer cell anchorage-independent growth by isorhapontigenin treatment. Together, our studies show that isorhapontigenin is an active compound that mediates Gnetum Cleistostachyum's induction of cell-cycle G0–G1 arrest and inhibition of cancer cell anchorage-independent growth through downregulating SP1/cyclin D1 axis in bladder cancer cells. Our studies provide a novel insight into understanding the anticancer activity of the Chinese herb Gnetum Cleistostachyum and its isolate isorhapontigenin. Mol Cancer Ther; 12(8); 1492–503. ©2013 AACR.

18 February 2019 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
HGHui‐Hui Guo
Hui‐Hui Guo
CMChen Ma
Chen Ma
WZWen‐Sheng Zheng
Wen‐Sheng Zheng
YLYang Luo
Yang Luo
CLCong Li
Cong Li
JJJian-dong Jiang
Jian-dong Jiang

1 December 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PLPeng Li
Peng Li
BWBin Wang
Bin Wang
XZXinwei Zhang
Xinwei Zhang
SBSarah M. Batt
Sarah M. Batt
GBGurdyal S. Besra
Gurdyal S. Besra
YLYu Lu
Yu Lu

19 February 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XWXu Wang
Xu Wang
YZYuna Zeng
Yuna Zeng
LSLi Sheng
Li Sheng
PLPeter Larson
Peter Larson
XLXue Liu
Xue Liu
CACourtney C. Aldrich
Courtney C. Aldrich